Objective: To identify the metabolic signature of the various levels of cognitive deficits in amyotrophic lateral sclerosis (ALS) using 18 F-2-fluoro-2-deoxy-D-glucose-PET ( 18 F-FDG-PET).
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease of the adult life affecting upper and lower motor neurons involving bulbar and spinal regions, characterized by progressive muscle weakness and wasting and limb spasticity. Besides motor impairment, extramotor abnormalities in ALS may include cognitive and behavioral changes falling within the frontotemporal lobar degeneration (FTLD) spectrum. Overall, ;15% of patients with ALS display a full-blown frontotemporal dementia (FTD), while ;35% have more subtle cognitive alterations involving executive and nonexecutive domains. 18 F-2-fluoro-2-deoxy-D-glucose-PET ( 18 F-FDG-PET) studies have shown hypometabolic clusters in frontal and temporal cortex as neurobiological correlates of ALS with comorbid FTD. 3 Moreover, 2 recent studies have shown that 18 F-FDG-PET can discriminate patients with ALS from healthy controls with accuracy close to 94%. 4, 5 Some studies reported a gradient of increasing brain atrophy assessed through structural MRI along the ALS-FTD continuum, ranging from pure ALS, through ALS with cognitive or behavioral deficits, to ALS with frank FTD. 6, 7 However, it is still unclear whether the clinical entities of such disease spectrum have distinct metabolic correlates reflecting the different degrees of cognitive impairment.
The aim of this study was to identify the metabolic signature of the various levels of cognitive deficits in ALS using 18 
F-FDG-PET.
METHODS Patients. A total of 170 patients with ALS who agreed to undergo both neuropsychological assessment and 18 F-FDG-PET were consecutively enrolled at the Turin ALS Center, Italy. All patients fulfilled the El Escorial Revised Diagnostic Criteria for definite, probable, or probable laboratory-supported ALS. 8 Patients were recruited at the time of diagnosis or during the first follow-up visit (2 months later). Neuropsychological evaluation and 18 F-FDG-PET were always performed within 1 month of each other and within 12 months from ALS diagnosis. Respiratory function was assessed for every subject within 4 weeks before or after neuropsychological evaluation and 18 F-FDG-PET. At the time of assessments, none of the patients showed oxygen saturation ,92% at pulse oximetry. Patients with a history of neurologic disorders affecting cognition (major stroke, severe head injuries, mental retardation), alcohol and drug dependence, severe mental illness, or use of high-dose psychoactive medications were not enrolled in the study, nor were patients whose mother tongue was not Italian.
Neuropsychological assessment. The selection of the neuropsychological tests, evaluating executive function, memory, visuospatial function, and language, was based on the Clinical Diagnostic Criteria for Frontotemporal Lobar Degeneration 9 and the ALS-FTD Consensus Criteria. 10 Non-FTD dementias were diagnosed according to the criteria of the DSM-IV-TR 11 ALS-Nc cases were excluded from subsequent analyses because the classification of this group as a distinct entity remains unclear.
18 F-FDG-PET was performed according to previously published guidelines. 13 PET/CT images were acquired by a Discovery ST-E System (General Electric; Fairfield, CT). CT scan of the brain (thickness 3.75 mm, 140k V, 60-80 mA/s) was followed by PET brain scan (1 field of view of 30 transaxial centimeters). Data were collected in 128 3 128 matrices; the reconstructed voxel was 2.34 3 2.34 3 2.00 mm.
Group comparison. Clinical characteristics of patients belong-
ing to different categories were compared using x 2 (discrete variables) or Student t test/analysis of variance (continuous variables). Data were analyzed using SPSS 21.0 statistical package (SPSS Inc., Chicago, IL). Detailed methods of group comparison of 18 F-FDG-PET data are provided elsewhere. 14 Preprocessing and statistical analyses were performed by SPM8 implemented in Matlab, 7.10.0. Scans were normalized by a 18 F-FDG-PET customized brain template, created at the same center and set up equally to the SPM8 default one. Group comparisons were carried out among ALS-Cn (n 5 94), ALS-FTD (n 5 20), ALSCi (n 5 37), and ALS-Bi (n 5 9) by the 2-sample t test model of SPM8, considering sex, type of onset, and age at PET as nuisance variables. The p , 0.001 threshold was used to create statistical parametric mapping t maps at peak and cluster level and the threshold of p , 0.05 corrected for multiple comparisons by false discovery rate was considered to be significant. If significant clusters were not found, the more liberal threshold at p , 0.001 uncorrected for multiple comparisons was considered. The coordinates of SPM isocenters were corrected by the subroutine implemented by Matthew Brett (http://brainmap.org/index.html) to match the Talairach coordinates. Brodmann areas were limited at a range of 0-3 mm and identified by Talairach client (http://www. talairach.org/index.html).
Standard protocol approvals, registrations, and patient consents. The study was approved by the institutional ethical committee of the Turin ALS Centre. All patients provided written informed consent before enrollment. Data were kept according to the Italian law for the protection of privacy.
RESULTS Clinical data. The clinical features of patients included in the analysis are summarized in table 1. We found no difference in sex, site of onset (bulbar/spinal), mean age at time of PET, mean time from diagnosis to PET scan, and Amyotrophic Lateral Sclerosis Functional Rating Scale-revised (ALSFRS-R) total score among groups. (figure, B) .
ALS-Cn vs ALS-Ci. In ALS-Ci at p , 0.001 uncorrected a relative hypometabolic cluster in right anterior cingulate, frontal and prefrontal cortex, as well as in left prefrontal cortex (figure, C, table 2) and a relative hypermetabolic cluster including midbrain and corticospinal tracts bilaterally were found ( figure, D) .
ALS-Ci vs ALS-FTD. Relative hypometabolism was found at p , 0.001 uncorrected in ALS-FTD in left orbitofrontal, prefrontal, and lateral frontal (Broca area) cortex (figure, E, table 2). Also in this comparison the most cognitively impaired group (ALS-FTD) showed a relative hypermetabolism in cerebellum, midbrain, and corticospinal tracts bilaterally at p , 0.001 uncorrected ( figure, F) .
No difference at the set statistical threshold was found between ALS-Bi and any other group. DISCUSSION This study analyzed the metabolic correlates of the different degrees of cognitive impairment in patients with ALS. We identified a decreasing gradient of frontal lobe metabolism going from ALS with normal cognition to ALS with FTD, through cases with intermediate cognitive deficits (ALS-Ci). According to these findings, ALS-Ci seems to represent a discrete category, showing less severe cognitive deficits and a distinct metabolic pattern as compared to ALS-FTD, being intermediate between pure ALS and ALS-FTD.
The groups with different degrees of cognitive impairment did not significantly differ in sex distribution, site of onset, mean age at PET examination, mean time from diagnosis to PET scan, or total ALSFRS-R score. However, we included these variables as nuisance in the 18 F-FDG-PET analyses and their contribution to data variability was kept under control.
We found a significantly reduced frontal and prefrontal metabolism in the ALS-FTD group as compared to patients with normal cognitive status. Furthermore, ALS-Ci showed in frontal cortex an intermediate metabolic behavior, being hypometabolic as compared to ALS-Cn, and demonstrating a cluster of higher relative metabolism as compared to ALS-FTD. Such cluster was included in the same left frontal regions found to be more severely hypometabolic in ALS-FTD as compared to ALS-Cn, suggesting a continuum between cognitive decline and metabolic activity in these areas. This finding is consistent with cognitive classification criteria and highlights the distinct metabolic pattern of ALS-Ci.
Our findings are in keeping with MRI studies comparing patients with ALS with different levels of cognitive impairment. A structural MRI study on 39 ALS cases reported that patients with ALS-FTD display significantly more atrophy of prefrontal and anterior temporal cortex as compared to patients with ALS with cognitive and behavioral symptoms not fulfilling FTD criteria (ALS-plus) and that the ALS-plus group shows significantly more atrophy than the pure ALS group in various areas including the superior frontal gyrus and the left planum temporale, supporting the hypothesis of a gradient of atrophy across groups. 6 Another MRI study showed that both patients with ALS-FTD and patients with ALS with cognitive impairment display cortical thinning of bilateral frontal and temporal cortex, with a more pronounced atrophy in the former group, suggesting the concept of a morphologic continuum reflecting the clinical one. 7 A possible advantage of 18 F-FDG-PET as compared to structural MRI is that abnormalities of Table 1 Clinical characteristics of patients according to cognitive categories ALS-Cn (n 5 94) ALS-FTD (n 5 20) ALS-Ci (n 5 37) ALS-Bi (n 5 9) Total (n 5 160) cortical metabolism may precede gray matter atrophy and therefore may be identified earlier along the disease course. This concept is supported by a study comparing brain structural MRI and metabolic 18 F-FDG-PET changes in brain gray matter of patients with ALS-FTD, showing metabolic alterations in most of the brain regions displaying structural changes but also isolated 18 F-FDG uptake reduction in some other areas. 15 In our study, hypometabolism in frontal regions was associated in all comparisons to hypermetabolism in cerebellum, midbrain, and corticospinal tracts: the more severe the cognitive decline, the larger the size of the cluster and the statistical significance of 18 F-FDG uptake differences (figure, B, D, and F) . This finding supports the hypothesis that astrocytosis, mainly in white matter, is associated with ALS neurodegeneration and possibly anticipates cortical changes. 14, [16] [17] [18] Overall, our results support the notion that patients with ALS with cognitive impairment not fulfilling FTD criteria represent a distinct category with a peculiar metabolic pattern placed between the 2 extremities of the ALS-FTD spectrum. This point is of outstanding importance, since the commixture of pure ALS cases with patients with ALS with cognitive deficits without frank FTD might produce inconsistent findings in the research on structural and functional correlates of cognitive impairment in ALS. 6 A neuropathologic staging system of the spreading of brain pathology in ALS has been proposed, based on the propagation of phosphorylated TDP-43 (pTDP-43) proteinopathy, since pTDP-43 aggregates seem to be strictly linked to neuron degeneration. 19 According to this model, pTDP-43 necessarily tends to spread with disease progression via axonal transport from the primary motor cortex to the prefrontal areas, suggesting that all patients with ALS are susceptible to develop frontal cognitive impairment over time, according to disease duration and rate of progression. 18 F-FDG-PET is a measure of neuronal injury and degeneration in vivo, 20 allowing prospective studies, unlike neuropathology. Therefore, functional neuroimaging might enrich neuropsychological testing in the longitudinal evaluation of cognitive impairment in ALS, providing early information on the spreading of brain pathology along disease progression.
Possible limitations of this study should be considered. First, we have no longitudinal data on brain metabolism in ALS-Ci patients. The area of the course of cognitive impairment over time in ALS remains largely unexplored. A few longitudinal studies with small sample size showed a limited, if any, deterioration of cognitive performance over time. [21] [22] [23] [24] [25] A recent larger population-based longitudinal study reported that patients with ALS displaying normal cognition at diagnosis tend to remain cognitively intact over time and that, in the absence of minimal alteration at baseline, executive dysfunction may arise in very late stages, if at all. Otherwise, patients with early executive or nonexecutive cognitive change may show a certain degree of spreading of cognitive impairment. 26 Second, we did not evaluate the possible role of cognitive reserve, a concept that has been proved to be valid for dementias other than frontotemporal syndromes related to ALS and that aims at explaining the possible mismatch between cerebral lesion load and clinical deficits we sometimes observe in clinical practice. Third, we could not characterize the metabolic pattern of ALS-Bi and ALS-Nc, because of the small size of these cognitive subgroups in our sample. On the other hand, a notable strength of this work is the high sample size (n 5 170), making it the largest survey on ALS including both neuropsychological assessment and 18 F-FDG-PET performed so far.
This study found in a large ALS cohort that frontal lobe metabolic impairment reflects the clinical and functional continuum ranging from ALS with normal cognition, through ALS with subtle, intermediate cognitive deficits, to ALS with comorbid FTD, and showed that patients with intermediate cognitive impairment display a characteristic metabolic pattern. 18 F-FDG-PET is considered a valuable tool to estimate the cerebral lesion load in vivo in neurodegenerative diseases. Our data indicate that it might be helpful to investigate the neurobiological basis of cognitive impairment in ALS along the disease course, since it can show the early regional spreading of brain metabolic alterations. Chiò had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. All authors have approved the submitted version of the article. Table 2 Results of 18 
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